This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orlowski, R. Z. Articles by Kuhn, D. J. Search for Related Content PubMed PubMed Citation Articles by Orlowski, R. Z. Articles by Kuhn, D. J. Related Collections Therapeutics and Targets Therapeutics and Targets: Experimental Therapeutics– Small Molecules Clinical Research: Clinical Trials

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

Authors' Affiliations: Departments of ¹ Lymphoma/Myeloma and ² Experimental Therapeutics, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Robert Z. Orlowski, The University of Texas M. D. Anderson Cancer Center, Department of Lymphoma/Myeloma, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030. Phone: 713-792-2860; Fax: 713-563-5067; E-mail: rorlowsk{at}mdanderson.org.

Abstract

The ubiquitin-proteasome pathway is involved in intracellular protein turnover, and its function is crucial to cellular homeostasis. First synthesized as probes of proteolytic processes, proteasome inhibitors began to be thought of as potential drug candidates when they were found to induce programmed cell death preferentially in transformed cells. They made their first leap into the clinic to be tested as therapeutic agents 10 years ago, and since then, great strides have been made in defining their mechanisms of action, their clinical efficacy and toxicity, and some of their limitations in the form of resistance pathways. Validation of the ubiquitin-proteasome pathway as a target for cancer therapy has come in the form of approvals of the first such inhibitor, bortezomib, for relapsed/refractory multiple myeloma and mantle cell lymphoma, for which this agent has become a standard of care. Lessons learned from this first-in-class agent are now being applied to the development of a new generation of proteasome inhibitors that hold the promise of efficacy in bortezomib-resistant disease and possibly in a broader spectrum of diseases. This saga provides a salient example of the promise of translational medicine and a paradigm by which other agents may be successfully brought from the bench to the bedside.

This article has been cited by other articles:

				T.-M. Yang, D. Barbone, D. A. Fennell, and V. C. Broaddus Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 14 - 23. [Abstract] [Full Text] [PDF]

				M. Nojima, R. Maruyama, H. Yasui, H. Suzuki, Y. Maruyama, I. Tarasawa, Y. Sasaki, H. Asaoku, H. Sakai, T. Hayashi, et al. Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma Clin. Cancer Res., July 1, 2009; 15(13): 4356 - 4364. [Abstract] [Full Text] [PDF]

				T. A. Soucy, P. G. Smith, and M. Rolfe Targeting NEDD8-Activated Cullin-RING Ligases for the Treatment of Cancer Clin. Cancer Res., June 15, 2009; 15(12): 3912 - 3916. [Abstract] [Full Text] [PDF]

				K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood, June 11, 2009; 113(24): 6069 - 6076. [Abstract] [Full Text] [PDF]

				D. J. Kuhn, S. A. Hunsucker, Q. Chen, P. M. Voorhees, M. Orlowski, and R. Z. Orlowski Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors Blood, May 7, 2009; 113(19): 4667 - 4676. [Abstract] [Full Text] [PDF]

				A. Delmonte, M. Ghielmini, and C. Sessa Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas Oncologist, May 1, 2009; 14(5): 511 - 525. [Abstract] [Full Text] [PDF]

				M. IIJIMA, I. MOMOSE, and D. IKEDA TP-110, a New Proteasome Inhibitor, Down-regulates IAPs in Human Multiple Myeloma Cells Anticancer Res, April 1, 2009; 29(4): 977 - 985. [Abstract] [Full Text] [PDF]

				R. C Smallridge, L. A Marlow, and J. A Copland Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies Endocr. Relat. Cancer, March 1, 2009; 16(1): 17 - 44. [Abstract] [Full Text] [PDF]

				J. Ruan, K. Hajjar, S. Rafii, and J. P. Leonard Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma Ann. Onc., March 1, 2009; 20(3): 413 - 424. [Abstract] [Full Text] [PDF]

				S. Dayal, A. Sparks, J. Jacob, N. Allende-Vega, D. P. Lane, and M. K. Saville Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53 J. Biol. Chem., February 20, 2009; 284(8): 5030 - 5041. [Abstract] [Full Text] [PDF]

				G. Pagnan, D. Di Paolo, R. Carosio, F. Pastorino, D. Marimpietri, C. Brignole, A. Pezzolo, M. Loi, L. J.V. Galietta, F. Piccardi, et al. The Combined Therapeutic Effects of Bortezomib and Fenretinide on Neuroblastoma Cells Involve Endoplasmic Reticulum Stress Response Clin. Cancer Res., February 15, 2009; 15(4): 1199 - 1209. [Abstract] [Full Text] [PDF]

				G. Bisping, D. Wenning, M. Kropff, D. Gustavus, C. Muller-Tidow, M. Stelljes, G. Munzert, F. Hilberg, G. J. Roth, M. Stefanic, et al. Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma Clin. Cancer Res., January 15, 2009; 15(2): 520 - 531. [Abstract] [Full Text] [PDF]

				P. G. Richardson, C. Mitsiades, J. Laubach, D. Chauhan, T. Hideshima, and K. Anderson Realizing the Anticancer Potential of Proteasome Inhibition: The Clinical Development of Bortezomib and Second-generation Proteasome Inhibitors ASCO Educational Book, January 1, 2009; 2009(1): 163 - 170. [Abstract] [Full Text] [PDF]

				X. Wang, H. Xu, D. Ju, and Y. Xie Disruption of Rpn4-Induced Proteasome Expression in Saccharomyces cerevisiae Reduces Cell Viability Under Stressed Conditions Genetics, December 1, 2008; 180(4): 1945 - 1953. [Abstract] [Full Text] [PDF]

				D. Plesca, S. Mazumder, V. Gama, S. Matsuyama, and A. Almasan A C-terminal Fragment of Cyclin E, Generated by Caspase-mediated Cleavage, Is Degraded in the Absence of a Recognizable Phosphodegron J. Biol. Chem., November 7, 2008; 283(45): 30796 - 30803. [Abstract] [Full Text] [PDF]

				R. Oerlemans, N. E. Franke, Y. G. Assaraf, J. Cloos, I. van Zantwijk, C. R. Berkers, G. L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, et al. Molecular basis of bortezomib resistance: proteasome subunit {beta}5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood, September 15, 2008; 112(6): 2489 - 2499. [Abstract] [Full Text] [PDF]

				G. C. Prendergast Refining Cytotoxic Therapy: Progress in Generalized Therapeutics for Cancer Cancer Reviews Online Content, April 1, 2008; 2008(4): 7 - 7. [Full Text] [PDF]